Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Intravitreal Chemotherapy (IViC)
Treatment for Retinoblastoma
Typical Dosage: e.g., Melphalan 20-40 "g, Topotecan 10-30 "g
Effectiveness
90%
Safety Score
50%
Clinical Trials
40
Participants
2.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
e.g., Melphalan 20-40 "g, Topotecan 10-30 "g
Time to Effect
2-4 weeks
Treatment Duration
1-3 months
Evidence Quality
MODERATEConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$30,000
Side Effect Mgmt:$1,000
Total Annual:$33,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
19
Outcome-Based Costs
Cost per Responder
$37,714
Cost per Remission
$37,714
Comparison vs Enucleation (salvage for vitreous seeds)
Cost Difference
+$15,500/year
More expensive
QALY Difference
+0.75 QALYs
Better outcomes
Dominance
No dominance
Intravitreal Chemotherapy (IViC) Outcomes
for Retinoblastoma
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+88%
Remission Rate
+88%
Common Side Effects
Vitreous hemorrhage
+10%
Retinal toxicity
+10%
Hyphema
+10%
Retinal detachment
+5%
Endophthalmitis
+1%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov